Inhibikase Therapeutics (IKT) Insider Trading & Ownership $2.80 +0.04 (+1.45%) (As of 04:00 PM ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends Inhibikase Therapeutics (NYSE:IKT) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage4.59%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$198,650.00Number OfInsiders Selling(Last 12 Months)0 Get IKT Insider Trade Alerts Want to know when executives and insiders are buying or selling Inhibikase Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address IKT Insider Buying and Selling by Quarter Ad Brownstone ResearchCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.Click here to see the details because I believe a lot of people will get rich. Inhibikase Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails10/21/2024Arvind KushDirectorBuy145,000$1.37$198,650.00 (Data available from 1/1/2013 forward) IKT Insider Trading Activity - Frequently Asked Questions Who is on Inhibikase Therapeutics's Insider Roster? The list of insiders at Inhibikase Therapeutics includes Arvind Kush, Joseph Frattaroli, and Milton H Werner. Learn more on insiders at IKT. What percentage of Inhibikase Therapeutics stock is owned by insiders? 4.59% of Inhibikase Therapeutics stock is owned by insiders. Learn more on IKT's insider holdings. Which Inhibikase Therapeutics insiders have been buying company stock? The following insider purchased IKT shares in the last 24 months: Arvind Kush ($198,650.00). How much insider buying is happening at Inhibikase Therapeutics? Insiders have purchased a total of 145,000 IKT shares in the last 24 months for a total of $198,650.00 bought. Inhibikase Therapeutics Key ExecutivesDr. Milton H. Werner Ph.D. (Age 60)CEO, President & Director Compensation: $697.96kMr. Garth Lees-Rolfe CPA (Age 39)Chief Financial Officer Dr. Surendra SinghHead of Chemistry, Manufacturing & ControlsDr. Charles Warren Olanow B.Sc.F.R.C.P.C., M.D., CEO of Clintrex Research Corporation & Member of Scientific Advisory BoardDan WilliamsController More Insider Trading Tools from MarketBeat Related Companies TSHA Insider Selling SANA Insider Selling PROK Insider Selling HUMA Insider Selling GLUE Insider Selling MGTX Insider Selling RGNX Insider Selling ALLO Insider Selling DNA Insider Selling AURA Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Zeta Global Holdings Insiders Buy Stock After Short-ReportServiceNow: Will the High-Flyer Finally Split in 2024?Insiders Selling Into 3 Rallies: Investors Should Do the OppositeInsiders Bet Big on These Small Cap StocksHere’s Why Etsy Management Is Investing $1 Billion in Buybacks This page (NYSE:IKT) was last updated on 12/3/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally c...Porter & Company | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibikase Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibikase Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.